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Accepted 7 March 2012Kallmann’s syndrome is characterized by hypogonado-
tropic hypogonadism and anosmia [1]. It is a rare disorder,
occurring in only one per 50,000 women [2]. Induction of
ovulation in women with hypogonadotropic hypogonadism
requires follicle-stimulating hormone (FSH) for follicular
growth, and both FSH and luteinizing hormone (LH) to induce
optimal follicular steroidogenesis and ovulation. Numerous
reports of achieving successful pregnancies in women with
Kallmann’s syndrome have appeared in the literature. Recent
evidence suggests that low-dose human chorionic gonado-
tropin (hCG) can also be used to mimic LH actions on
developing follicles in a more sustained and stable manner,
permitting the progression of folliculogenesis when the LH/
hCG receptors begin to be expressed in the granulose cells of
larger ovarian follicles [3]. More specifically, serum levels of
hCG during human menopausal gonadotropin (hMG) admin-
istration were inversely correlated with the occurrence of
small preovulatory follicles [4]. We describe here a woman
with Kallmann’s syndrome who was treated with a combina-
tion of hMG and low-dose hCG to achieve ovulation induction
and successful pregnancy.
A 29-year-old woman was referred to our hospital for
investigation and treatment of infertility. She was first seen at
the age of 19 years with a complaint of primary amenorrhea,
having presented without any secondary characteristics and
anosmia. She had very low serum gonadotropin and estrogen
levels, and inadequate responses to repeated gonadotropin-
releasing hormone (GnRH) tests. In addition, olfactory
magnetic resonance imaging (MRI) revealed olfactory tract
agenesis. She was diagnosed with Kallmann’s syndrome and* Corresponding author. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital, 5 Fu-Shin Street, Kweishan, Taoyuan 363, Taiwan.
E-mail address: yks@cymh.org.tw (Y.-K. Soong).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2012.04.027had irregularly taken oral contraception since then. When she
later presented to our reproductive center at 29 years old,
physical examination revealed her to be overweight (body
mass index ¼ 27.6 kg/m2), at Tanner stage 3 for breast
development, and at Tanner stage 2 for pubic and axillary hair.
The serum level of FSH and LH concentration was < 0.5 IU/
L, and the estradiol (E2) concentration was 13 pmol/L. Her
serum prolactin and thyroid-stimulating hormone levels were
within normal range. The patient complained of anosmia. She
did not have color blindness, visual abnormalities, or any other
congenital abnormalities. Her husband’s semen analysis was
normal.
To induce the gonadotropin receptors at the ovarian level,
we administered hormone therapy with estrogen and proges-
terone to reprogram the menstrual cycle before ovarian stim-
ulation. Follicular stimulation was initiated with human
menopausal gonadotropin (Menopur, Ferring Pharmaceuticals
Ltd, Germany) at a dose of 150 IU/day for 6 days starting on
Day 1 of her menstrual cycle. On cycle Day 6,100 IU of
recombinant human FSH (Puregon, Organon Laboratories Ltd,
Cambridge, UK) was introduced, because an adequate follic-
ular development and serum level of E2 had not been ach-
ieved. After 23 days of treatment, the patient had only one
dominant follicle that had reached a diameter of > 1.6 cm.
There was an appropriate endometrial thickening of 13 mm
and a serum E2 level of 1117 pmol/L. On Day 24, 5000 IU of
hCG (Profasi, Serono, Italy) was administered intramuscularly
for ovulation. The total dose of FSH was 1800 IU, which was
given over 18 days of stimulation. Intrauterine insemination
(IUI) was performed 36 hours after the injection of hCG. On
the day following the IUI, micronized progesterone at 400 mg
daily was started to provide luteal phase support. Unfortu-
nately, the woman did not become pregnant and suffered from
withdrawal bleeding 2 weeks later.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Methods of ovulation induction in women with previously diagnosed Kallmann’s syndrome since 1990.
Year (reference no.) Stimulation No. of follicles sized
> 1.6 cm on hCG day
Max. E2 level
(pmol/L)
No. of pregnancies
(patients)
1992 (11) Leuprolide acetate followed by hMG a a 1 (1)
1995 (2) Pulsatile GnRH or hMG a a 9 (3)
1996 (12) Recombinant FSH and LH 1 760 1 (1)
1998 (13) hMG Mean 2.5 Mean 1540.6 5 (3)
2000 (14) Highly purified FSH 3 a 1 (1)
2001 (15) hMG a a 1 (1)
2005 (16) hMG 2 a 1 (1)
2007 (17) hMG pretreated with testosterone patch 1 348 0 (1)
2007 (18) hMG 1 235 1 (1)
Case hMG followed by low-dose hCG 4 1952 1 (1)
FSH ¼ follicle-stimulating hormone; GnRH ¼ gonadotropin-releasing hormone; hCG ¼ human chorionic gonadotropin; hMG ¼ human menopausal gonado-
tropin; LH ¼ luteinizing hormone.
a Information not available.
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the same dose of hMG (150 IU/day). During the ovarian
stimulation, we monitored the follicular growth and serum E2
concentration. After 20 days of treatment, 200 IU of hCG per
day were added, and after Day 27, 112.5 IU/day FSH (Gonal
F, Serono Laboratories, Rome, Italy) were added. After 35
days of stimulation, an endometrial thickness of 13 mm, four
follicles with a mean diameter of > 1.6 cm, and a serum E2
level of 1952 pmol/L were obtained. Trigger ovulation was
administered with 5000 IU hCG, followed by an IUI 2 days
later. The total dose of FSH was 900 IU, which was given for 8
days. The patient conceived and an ultrasound scan confirmed
a viable twin intrauterine pregnancy. Two healthy infants
weighing 2685 g and 2355 g were delivered via cesarean
section at a gestational age of 36 weeks.
Kallmann’s syndrome, a disorder characterized by hypo-
gonadism resulting from hypogonadotropism and anosmia,
was first reported as a genetic syndrome by Kallmann et al. in
1944 [1]. The incidence of the condition in women is
approximately 1:50,000 [2]. It may be associated with some
congenital abnormalities, including midline defects (e.g., cleft
lip, palate, and transverse facial cleft), renal abnormalities
(agenesis), color blindness, neurosensorial deafness, and
platelet dysfunction.
Infertility in women with Kallmann’s syndrome results
from inadequate hypothalamic secretion of GnRH character-
ized by very low FSH and LH. Consequently, these hormones
need to be replaced and ovulation induction is necessary to
achieve pregnancy. Various ovulation induction treatments
have been attempted for infertile women with this syndrome,
such as using pulsatile GnRH, FSH and LH, or hMG [5e10].
In the literature, few pregnancies in women with Kallmann’s
syndrome have been reported since 1990 (Table 1) [2,11e18].
To our knowledge, the case reported herein is the first pub-
lished case in which low-dose hCG was used in the mid-to-late
follicular phase, in conjunction with an IUI, to achieve preg-
nancy in a woman with Kallmann’s syndrome.
Although ovulation induction using purified FSH or
recombinant FSH for infertile women with Kallmann’ssyndrome has been previously attempted, these gonadotropins
may produce an inadequate estradiol level, require more
ampoules of menotropin, and result in fewer preovulatory
follicles and a reduced occurrence of ovulation. We there-
fore selected low-dose hMG initially for triggering ovulation
induction. The main difference in ovulation induction app-
roach between the first and second cycle was making use of
hCG in the mid-to-late follicular phase. With our patient, low-
dose hCG was used in mid-to-late follicular phase of the
second cycle and resulted in a higher E2 level (1952 vs.
1117 pmol/L), more larger preovulatory follicles, and fewer
small preovulatory follicles. We also had more dominant
follicles and higher E2 levels compared to the previous case
reports (Table 1).
Early follicular phase prevalence of FSH is essential to
follicle recruitment, whereas later LH increments are crit-
ical for dominant follicle selection and maturation at a time
of declining FSH levels [19]. The granulosa cells (GC) of
the larger follicles (roughly following achievement of a 10-
mm diameter) become responsive to LH through the
expression of LH/hCG receptors induced by FSH and
estrogens [20], thus making them sensitive to LH activity
stimulation. Filicori et al. [3] demonstrated that the
administration of low-dose hCG in the last 3e4 days of
ovarian stimulation was associated with a more estrogenized
intrafollicular environment, fewer small preovulatory folli-
cles, higher fertilization rates, and no signs of premature
luteinization. A recent study obtained similar results when
assessing the use of selective hCG in the late follicular
phase in a larger series [21].
In our case, the effect of using low-dose hCG in the late
follicular phase was the same as in previous studies. For this
reason, we believe that low-dose hCG may play a role in
inducing a higher hyperestrogenized environment and attain-
ing follicular growth synchronization.
In conclusion, administering hMG in combination with
a low-dose of hCG in the mid-to-late follicular phase may be
used in women with Kallmann’s syndrome for ovulation
induction and pregnancy.
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